Etoposide
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Etoposide (VP-16)是第一个识别的作为抗癌药物的拓扑异构酶II抑制剂,IC50值为59.2 μM。
Etoposide可以阻断拓扑异构酶II对DNA链重新连接的活性。Etoposide与DNA形成三元复合物,引起DNA链断裂[1]。由于癌细胞的分裂更为迅速,因而该酶在癌细胞中的作用比健康细胞中更重要。因此,etoposide可诱导癌细胞的凋亡[2]。 Etoposide对HepG2和MOLT-3癌细胞具有细胞毒性效应,IC50值分别为30.16 μM和0.051 μM[3]。Etoposide对BGC-823、HeLa和A549癌细胞系的IC50值分别为43.74 ± 5.13、209.90 ± 13.42和139.54 ± 7.05 μM[4]。
参考文献:
[1]. Pommier Y, Leo E, Zhang H, Marchand C. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol. 2010 May 28;17(5):421-33.
[2]. Gordaliza M, García PA, del Corral JM, Castro MA, Gómez-Zurita MA. Podophyllotoxin: distribution, sources, applications and new cytotoxic derivatives. Toxicon. 2004 Sep 15;44(4):441-59.
[3]. Pingaew R, Mandi P, Nantasenamat C, Prachayasittikul S, Ruchirawat S, Prachayasittikul V. Design, synthesis and molecular docking studies of novel N-benzenesulfonyl-1,2,3,4-tetrahydroisoquinoline-based triazoles with potential anticancer activity. Eur J Med Chem. 2014 May 6;81C:192-203.
[4]. Xiao L, Zhao W, Li HM, Wan DJ, Li DS, Chen T, Tang YJ. Design and synthesis of the novel DNA topoisomerase II inhibitors: Esterification and amination substituted 4'-demethylepipodophyllotoxin derivates exhibiting anti-tumor activity by activating ATM/ATR signaling pathways. Eur J Med Chem. 2014 Jun 10;80:267-77.
- 1. Phoebe McCrorie, Jatin Mistry, et al. "Etoposide and olaparib polymer-coated nanoparticles within a bioadhesive sprayable hydrogel for post-surgical localised delivery to brain tumours." Eur J Pharm Biopharm. 2020 Oct 14;S0939-6411(20)30305-2. PMID:33068736
- 2. Cai B, Hu Z, et al. "Triptolide impairs genome integrity by directly blocking the enzymatic activity of DNA-PKcs in human cells." Biomed Pharmacother. 2020;129:110427. PMID:32574974
- 3. Zhao K, Wang X, et al. "A long noncoding RNA sensitizes genotoxic treatment by attenuating ATM activation and homologous recombination repair in cancers." PLoS Biol. 2020;18(3):e3000666. PMID:32203529
- 4. Wang Z, Chen J, et al. "cGAS/STING axis mediates a topoisomerase II inhibitor-induced tumor immunogenicity." J Clin Invest. 2019 Aug 13;130:4850-4862. PMID:31408442
- 5. Barot S, Abo-Ali EM, et al. "Inhibition of glycogen catabolism induces intrinsic apoptosis and augments multikinase inhibitors in hepatocellular carcinoma cells." Exp Cell Res. 2019 Aug 15;381(2):288-300. PMID:31128107
- 6. Rogers C, Erkes DA, et al. "Gasdermin pores permeabilize mitochondria to augment caspase-3 activation during apoptosis and inflammasome activation." Nat Commun. 2019 Apr 11;10(1):1689. PMID:30976076
- 7. Wu Q, Wei X, et al. "Bionic 3D spheroids biosensor chips for high-throughput and dynamic drug screening." Biomed Microdevices. 2018 Sep 15;20(4):82. PMID:30220069
- 8. Lochmann TL, Floros KV, et al. "Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression." Clin Cancer Res. 2018 Jan 15;24(2):360-369. PMID:29118061
- 9. Xia L, Xiao X, et al. "Coactosin-like protein CLP/Cotl1 suppresses breast cancer growth through activation of IL-24/PERP and inhibition of non-canonical TGFβ signaling." Oncogene. 2018 Jan 18;37(3):323-331. PMID:28925397
Physical Appearance | A solid |
Storage | Store at -20℃ |
M.Wt | 588.56 |
Cas No. | 33419-42-0 |
Formula | C29H32O13 |
Solubility | ≥29.45 mg/mL in DMSO; insoluble in H2O; insoluble in EtOH |
Chemical Name | (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one |
SDF | Download SDF |
Canonical SMILES | CC1OCC2C(O1)C(C(C(O2)OC3C4COC(=O)C4C(C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O |
运输条件 | 蓝冰运输或根据您的需求运输。 |
一般建议 | 不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。 |
激酶实验 [1]: | |
拓扑异构酶II活性测定 |
制备核提取物并将细胞核分离。以去连环百分比计算拓扑异构酶II活性。氚标记的含动基体DNA(KDNA 0.22 μg)作为底物。将Etoposide和拓扑异构酶II置于37℃孵育30分钟,再使用1%十二烷基硫酸钠(SDS)和蛋白酶K(100 μg/mL)终止反应。测得Etoposide对拓扑异构酶II的抑制和去连环百分比。 |
细胞实验 [2]: | |
细胞系 |
BGC-823细胞、HeLa细胞和A549细胞 |
制备方法 |
在DMSO中的溶解度大于10 mM。若配制更高浓度的溶液,一般步骤如下:请将试管置于37℃加热10分钟和/或将其置于超声波浴中震荡一段时间。原液于-20℃可放置数月。 |
反应条件 |
0.5, 1, 10, 20, 50, 100, 200和500 μM;2天 |
试验结果 |
Etoposide对肿瘤细胞系BGC-823、HeLa以及A549的IC50值分别为43.74 ± 5.13 μM、209.90 ± 13.42 μM和139.54 ± 7.05 μM。 |
动物实验 [3]: | |
动物模型 |
鼠血管肉瘤细胞ISOS-1异种移植模型 |
给药剂量 |
2.5, 5, 10 mg/kg;腹腔注射;每天1次,持续5天 |
实验结果 |
腹腔注射10 mg/kg Etoposide能抑制鼠血管肉瘤细胞ISOS-1肿瘤。 |
其他注意事项 |
请于室内测试所有化合物的溶解度。虽然化合物的实际溶解度可能与其理论值略有不同,但仍处于实验系统误差的允许范围内。 |
References: [1]. Beauchesne P, Bertrand S, N'guyen MJ, Christianson T, Dore JF, Mornex F, Bonner JA. Etoposide sensitivity of radioresistant human glioma cell lines. Cancer Chemother Pharmacol. 1998;41(2):93-7. [2]. Xiao L, Zhao W, Li HM, Wan DJ, Li DS, Chen T, Tang YJ. Design and synthesis of the novel DNA topoisomerase II inhibitors: Esterification and amination substituted 4'-demethylepipodophyllotoxin derivates exhibiting anti-tumor activity by activating ATM/ATR signaling pathways. Eur J Med Chem. 2014 Jun 10;80:267-77. [3]. Ma G1, Masuzawa M, Hamada Y, Haraguchi F, Tamauchi H, Sakurai Y, Fujimura T, Katsuoka K. Treatment of murine angiosarcoma with etoposide, TNP-470 and prednisolone. J Dermatol Sci. 2000 Nov;24(2):126-33. |
质量控制和MSDS
- 批次: